Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics An Exclusive Option To License PCS12852; Strengthens Balance Sheet With $7M Capital Infusion

Author: Benzinga Newsdesk | July 01, 2025 09:19am
  • Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852
  • Continue enrolling patients in Phase 2 study of PCS6422
  • Strengthened balance sheet with $7M capital infusion

     

VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.

Posted In: PCSA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist